Merck Begins Dosing First Patient in Phase III Trial of Oral Cladribine for gMG
Merck, a prominent science and technology company, has announced that the first patient has been dosed in the Phase III MyClad trial (NCT06463587), which is investigating the efficacy and safety of oral cladribine for the treatment of generalized Myasthenia Gravis…